
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Catch up on the first three episodes of our Molecular Imaging in Focus series featuring interviews with Gary Ulaner, MD, PhD, Louise Emmett, MBChB, FRACP, FAANMS, MD, and Jeremie Calais, MD, PhD.
We take a look back at the first three episodes of our new Molecular Imaging in Focus series with topics ranging from the potential of the emerging radiodiagnostic agent 61Cu-NU101 and recent findings from the Co-PSMA trial with 64Cu-SAR-bisPSMA to the utility of PSMA PET in risk stratification for patients with prostate cancer. Review the slideshow below to watch the first three episodes.




